嵌合抗原受体 T 细胞 (CAR-T) 疗法是一种免疫疗法，涉及对患者自身 T 细胞进行基因改造，使其表达嵌合抗原受体，使其能够识别并消灭癌细胞。这种治疗彻底改变了血液恶性肿瘤的预后和治疗，导致长期幸存者显着增加。然而，由于这种疗法最近出现，关于晚期后遗症和治疗后护理的证据有限。 CAR-T 疗法的快速发展为高级执业护士创造了机会，让他们在协调护理、提供教育和确保幸存者的持续福祉方面发挥关键作用。本文概述了 CAR-T 疗法的长期幸存者所面临的身体、心理和经济挑战，并提出了解决这些问题的综合护理计划。© 2024 作者。

Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy that involves genetically modifying the patient's own T cells to express a chimeric antigen receptor, enabling them to recognize and destroy cancer cells. This treatment has revolutionized the prognosis and management of hematological malignancies, leading to a significant increase in long-term survivors. However, there is limited evidence regarding late sequelae and post-treatment care due to the recent emergence of this therapy. The rapid advancement of CAR-T therapies has created opportunities for advanced practice nurses to play a crucial role in coordinating care, providing education, and ensuring the ongoing well-being of survivors. This article provides an overview of the physical, psychosocial, and financial challenges faced by long-term survivors of CAR-T therapy and proposes a comprehensive nursing care plan to address these issues.© 2024 The Authors.